Phio CEO to Speak at Wainwright Conference in New York in September
September 06 2023 - 7:30AM
Phio Pharmaceuticals (Nasdaq: PHIO), a clinical
stage biotechnology company whose proprietary INTASYL™ RNAi
platform technology is designed to make immune cells more effective
in killing tumor cells, today announced that its President and CEO,
Robert Bitterman, will be presenting at the H.C. Wainwright 25th
Annual Global Investment Conference in New York on September 11th.
Mr. Bitterman will discuss the recent FDA IND approvals for
Phio’s lead product, PH-762; PH-762 is currently cleared for two
clinical trials. Mr. Bitterman will also review the Company’s
evolution from discovery to development, highlighting the new,
industry-experienced leadership team he has put in place to lead
this transformation.
The presentation will become available online at 7:00 am EST on
Monday, September 11th. It will be streamed here.The Conference
will be taking place September 11th—13th at the Lotte New York
Palace Hotel in New York City.
About Phio Pharmaceuticals Corp.Phio
Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage
biotechnology company whose proprietary INTASYL™ RNAi technology is
designed to make immune cells more effective in killing tumor
cells. INTASYL is the only self-delivering RNAi technology focused
on immuno-oncology therapeutics. INTASYL drugs precisely target
specific proteins that reduce the body’s ability to fight cancer,
without the need for specialized formulations or drug delivery
systems.For additional information, visit the Company’s website,
www.phiopharma.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such as
"intends," "believes," "anticipates," "indicates," "plans,"
"expects," "suggests," "may," "would," "should," "potential,"
"designed to," "will," "ongoing," "estimate," "forecast," "target,"
"predict," "could" and similar references, although not all
forward-looking statements contain these words. These statements
are based only on our current beliefs, expectations and assumptions
and are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict and many of which are
outside of our control. Our actual results may differ materially
from those indicated in the forward-looking statements as a result
of a number of important factors, including, but not limited to,
the impact to our business and operations by inflationary
pressures, rising interest rates, recession fears, the development
of our product candidates, results from our preclinical and
clinical activities, our ability to execute on business strategies,
our ability to develop our product candidates with collaboration
partners, and the success of any such collaborations, the timeline
and duration for advancing our product candidates into clinical
development, the timing or likelihood of regulatory filings and
approvals, the success of our efforts to commercialize our product
candidates if approved, our ability to manufacture and supply our
product candidates for clinical activities, and for commercial use
if approved, the scope of protection we are able to establish and
maintain for intellectual property rights covering our technology
platform, our ability to obtain future financing, market and other
conditions and those identified in our Annual Report on Form 10-K
and subsequent Quarterly Reports on Form 10-Q under the caption
"Risk Factors" and in other filings the Company periodically makes
with the SEC. Readers are urged to review these risk factors and to
not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. Phio does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release, except as
required by law.
Contact:Phio Pharmaceuticals
Corp.ir@phiopharma.com
PR ContactMichael AdamsBridge View
Mediaadams@bridgeviewmedia.com
Phio Pharmaceuticals (NASDAQ:PHIO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Phio Pharmaceuticals (NASDAQ:PHIO)
Historical Stock Chart
From Aug 2023 to Aug 2024